RecruitingPhase 2NCT06126510

Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Principal Investigator
Lu Xie, Medical PhD
Peking University People's Hospital
Intervention
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)(drug)
Enrollment
40 target
Eligibility
18-75 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06126510 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma

← Back to all trials